Active substanceTaurineTaurine
Similar drugsTo uncover
  • Dibicor®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Dibicor®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Igrele®
    drops d / eye 
    KVADRAT-S, LLC     Russia
  • CardioActiv® Taurine
    pills inwards 
    EVALAR, CJSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    UPDATE OF PFC, CJSC     Russia
  • Taurine
    drops d / eye 
    VIFITEH, CJSC     Russia
  • Taurine
    solution
    DALHIMFARM, OJSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    Firm VIPS-MED, LLC     Russia
  • Taurine
    films d / eye 
    Progress RCC, JSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    Company DEKO, LLC     Russia
  • Taurine
    drops d / eye 
  • Taurin-Akos
    drops d / eye 
    SYNTHESIS, OJSC     Russia
  • Taurin-DIA
    drops d / eye 
  • Taurin-SOLOFARM
    drops d / eye 
    GROTEKS, LLC     Russia
  • Taufon
    drops d / eye 
  • Dosage form: & nbspeye drops
    Composition:

    1 ml of the solution contains:

    Active substance: taurine 40 mg Excipients:

    methylparahydroxybenzoate (methylparaben) 1 mg

    1 M sodium hydroxide solution to pH 5.0-6.5

    water for injection up to 1 ml

    Description:clear, colorless liquid.
    Pharmacotherapeutic group:metabolic
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Taurine is a sulfur-containing amino acid that forms in the body during the conversion of cysteine. Stimulates the processes of reparation and regeneration in diseases of a dystrophic nature and diseases accompanied by

    a sharp violation of the metabolism of the eye tissues.

    Promotes the normalization of the functions of cell membranes, the activation of energy and metabolic processes, the preservation of the electrolyte composition of the cytoplasm behind accumulation account K+ and Ca2+, improving the conditions for carrying out a nerve impulse.

    Pharmacokinetics:With topical application, systemic absorption is low.
    Indications:

    The drug is administered to adults with:

    -Dystrophy of the cornea;

    -Star, traumatic, radiation and other types of cataracts;

    - Trauma of the cornea (as a stimulant of reparative processes);

    - Primary open-angle glaucoma in combination with (β-adrenoblockers (to improve the outflow of watery moisture).

    For all indications, the drug is used as part of complex therapy.

    Contraindications:Individual hypersensitivity to taurine, children under 18 years of age.
    Pregnancy and lactation:

    Sufficient experience in the use of the drug during pregnancy, breast-feeding is not. It is possible to use Taufon to treat pregnant and lactating mothers as prescribed by the doctor if the expected therapeutic effect exceeds the risk of possible side effects.

    Dosing and Administration:

    With cataracts, Taufon is prescribed in the form of instillations for 1-2 drops 2-4 times a day for three months. The course is repeated at a monthly interval.

    In injuries and dystrophic diseases, corneas are used in the same doses for one month.

    With open-angle glaucoma (in combination with butylamine hydroxypropoxy-phenoxymethyl-methyloxadiazole and its combined forms or timolol) - 1-2 drops 2 times a day, for 15-20 min before the appointment of one of the antihypertensive drugs, for 6 weeks, followed by cancellation for 2 weeks.

    Side effects:allergic reactions. If the side effects indicated in the manual are aggravated, or if you notice any other side effects not listed in the instructions, inform the doctor about it.
    Overdose:

    Data on overdose are absent.

    Interaction:

    In patients with glaucoma (open-ended), a significant increase in the antihypertensive effect of β-adrenoblockers (timolol and butylamine hydroxypropoxyphenoxymethyl methyl oxadiazole) in the case of combined use with Taufon.

    Strengthening the effect is achieved by increasing the coefficient of ease of outflow and reducing the production of aqueous humor.

    Special instructions:
    Form release / dosage:

    Eye drops 4%.

    1.5 ml, 2 ml or 5 ml in a tube-droppers polymer.

    1, 2, 4, 5 or 10 tubes of intravenous drip with instructions for use of the preprata in a pack of cardboard.

    5 ml or 10 ml in the vial-droppers polymer.

    1 or 2 bottles of IV dripthe use of the drug in a pack of cardboard.

    Instructions for use text a tube-dropper or vial-A dropper is applied on the pack.

    5 ml into glass bottles. 1 bottle complete with lid-a dropper in sterile design and instruction on the use of the preprata in a pack of cardboard.

    5 bottles in a contour packing from polyvinylchloride filmreadable. 1 circuit cell packaging complete with 5 drop capsin sterile design and instruction on the use of the preparationthat in a pack of cardboard.

    Storage conditions:

    In the dark place at temperature not higher than 15 ° С (for the preparate in a tube-droppers).

    In the dark place at a temperature of no higher than 25 ° C (for the drug in the bottle-droppers and bottles).

    Keep out of the reach of children.

    Shelf life:

    2 years in a tube-droppers.

    3 years in a bottle-droppers.

    4 years in vials.

    Shelf life after the opening - 1 month.

    Do not use after expiration. shelf life, the on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-001210
    Date of registration:12.09.2011
    The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp03.09.2015
    Illustrated instructions
      Instructions
      Up